GlobeNewswire·Aug 10, 2026, 4:24 PM ET

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Enrollment continues across all indications in Ntrust-1 & Ntrust-2 trials at the 4 billion cell dose level (12 billion cells in a 3-dose cycle).
Initial clinical data from Ntrust-1 & Ntrust-2 is expected to be presented at a medical conference in 2026.
Outpatient dosing of NKX019 is underway via a network of community-based sites following an FDA agreement on dosing location.
Cash balance was $243.2 million as of June 30, 2026, which is expected to fund operations into 2029.
Research & development expenses were $29.0 million for the second quarter of 2026, including $0.7 million in non-cash stock-based compensation.
General & administrative expenses were $14.1 million for the second quarter of 2026, including $1.1 million in non-cash stock-based compensation.
Net loss for the second quarter of 2026 was $40.4 million, or $0.54 per share, which included $11.8 million in non-cash charges.
Ntrust-1 & Ntrust-2 are multi-center, open-label trials evaluating NKX019 for systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, & primary membranous nephropathy.
Patients in the trials receive a three-dose cycle of NKX019 following lymphodepletion without supplemental cytokines or antibody-based therapeutics.
NKX019 is an allogeneic, off-the-shelf CAR-NK cell therapy engineered with a CD19-directed receptor & membrane-bound IL-15 to target pathogenic B cells.